Re-evaluating perioperative and neoadjuvant immunotherapy in early-stage lung cancer: Current evidence and discussions Erken evre akciğer kanserinde perioperatif ve neoadjuvan immünoterapinin yeniden değerlendirilmesi: Mevcut kanıtlar ve tartışmalar

Creative Commons License

Erul E.

Tuberkuloz ve Toraks, vol.73, no.1, pp.80-84, 2025 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 73 Issue: 1
  • Publication Date: 2025
  • Doi Number: 10.5578/tt.2025011040
  • Journal Name: Tuberkuloz ve Toraks
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, CAB Abstracts, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.80-84
  • Keywords: Early-stage lung cancer, immune checkpoint inhibitors, neoadjuvant immunotherapy, non-small cell lung cancer, perioper-ative treatment
  • Ankara University Affiliated: Yes

Abstract

Early-stage lung cancer remains a challenging disease with a significant risk of recurrence despite treatment. In recent years, there has been growing interest in the application of neoadjuvant and perioperative immunotherapies. The success of immune checkpoint inhibitors in advanced stages has prompted their investigation in earlier disease stages. This editorial examines clinical trials comparing the efficacy of perioperative and neoadjuvant immunotherapies, focusing on their impact on survival, pathological response rates, and toxicity profiles. Furthermore, ongoing debates and the importance of patient-centered decision-making are discussed.